Adcetris 50mg Pulver,1 x 1Stk(brentuximab vedotin)

Reference priceCNY ¥630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	ADCETRIS
Manufacturer	Takeda chemical industries, Ltd.
Prescription required	Yes

Description

Adcetris 50mg Pulver,1 x 1Stk(brentuximab vedotin) is a medicine catalog record in the MediPriceHub database. Active ingredient: brentuximab vedotin. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Takeda chemical industries, Ltd.. Therapeutic category: Medicine Library > Oncology Medicines > Drugs for Hodgkin's disease. Pack information: 50 / 1. Origin country or market: Germany. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine . • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide . • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation . • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates . • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone . • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen . • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy . • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a ri

How to Use

Use brentuximab vedotin under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: brentuximab vedotin. Pack size: 50 / 1. Pack unit: bottle. Manufacturer: Takeda chemical industries, Ltd.. Origin country: Germany. Source category: Medicine Library > Oncology Medicines > Drugs for Hodgkin's disease. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

以上内容仅供参考。使用药品前请咨询合格的医疗专业人士。